sv3
As filed with the Securities and Exchange Commission on
December 21, 2007
Registration
No. 333-
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form S-3
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF
1933
Aradigm Corporation
(Exact name of registrant as
specified in its charter)
|
|
|
California
|
|
94-3133088
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
3929 Point Eden Way
Hayward, California 94545
(510) 265-9000
(Address, including zip code,
and telephone number,
including area code, of
registrants principal executive offices)
Igor Gonda
President and Chief Executive Officer
3929 Point Eden Way
Hayward, California 94545
(510) 265-9000
(Name, address, including zip
code, and telephone number,
including area code, of agent
for service)
Copies to:
James Kitch, Esq.
Peter Werner, Esq.
Cooley Godward Kronish LLP
101 California Street, 5th Floor
San Francisco, CA 94111
(415) 693-2000
Approximate date of commencement of proposed sale to the
public: From time to time after the effective
date of this registration statement
If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans,
please check the following
box. o
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest
reinvestment plans, check the following
box. þ
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the
following
box. o
If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to
register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities
Act, check the following
box. o
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Proposed Maximum
|
|
|
|
Title of Each Class of
|
|
|
Aggregate Offering
|
|
|
Amount of
|
Securities to be Registered
|
|
|
Price(2)
|
|
|
Registration Fee
|
Common Stock, no par value per share(1)
|
|
|
$60,000,000
|
|
|
$1,842
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Each share of common stock includes
an associated preferred stock purchase right under the Rights
Agreement, dated December 1, 2005, between the registrant
and Computershare Trust Company, as rights agent, as amended.
|
|
(2)
|
|
Estimated solely for the purpose of
calculating the registration fee in accordance with
Rule 457(o) under the Securities Act.
|
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these
securities in any state where the offer or sale is not
permitted.
|
SUBJECT TO COMPLETION, DATED
DECEMBER 21, 2007
PROSPECTUS
ARADIGM CORPORATION
$60,000,000
Common Stock
From time to time, we may offer up to $60,000,000 of our common
stock, no par value per share, pursuant to this prospectus.
We may offer the shares from time to time at prevailing market
prices, at prices related to prevailing market prices or at
privately negotiated prices. We will provide the specific terms
of these offerings in one or more supplements to this
prospectus. We may also authorize one or more free writing
prospectuses to be provided to you in connection with these
offerings. The prospectus supplement and any related free
writing prospectus may also add, update or change information
contained in this prospectus. You should carefully read this
prospectus, the applicable prospectus supplement and any related
free writing prospectus, as well as any documents incorporated
by reference, before buying any of the common stock being
offered.
Our common stock is traded on the OTC Bulletin Board under
the symbol ARDM. On December 20, 2007, the last
reported sale price of our common stock on the OTC
Bulletin Board was $1.50.
Investing in our common stock involves a high degree of
risk. You should review carefully the risks and uncertainties
described under the heading Risk Factors
contained in the applicable prospectus supplement and any
related free writing prospectus, and under similar headings in
the other subsequently filed documents that are incorporated by
reference into this prospectus.
This prospectus may not be used to consummate a sale of any
common stock unless accompanied by a prospectus supplement.
The common stock may be sold directly by us to investors,
through agents designated from time to time or to or through
underwriters or dealers, on a continuous or delayed basis. For
additional information on the methods of sale, you should refer
to the section entitled Plan of Distribution in this
prospectus. If any agents or underwriters are involved in the
sale of any securities with respect to which this prospectus is
being delivered, the names of those agents or underwriters and
any applicable fees, commissions, discounts and over-allotment
options will be set forth in a prospectus supplement. The price
to the public of those securities and the net proceeds that we
expect to receive from that sale will also be set forth in a
prospectus supplement.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus is December 21, 2007
TABLE OF
CONTENTS
This prospectus is part of a registration statement on
Form S-3
that we filed with the Securities and Exchange Commission, or
the SEC, utilizing a shelf registration process.
Under this shelf registration process, we may offer and sell
from time to time in one or more offerings the common stock
described in this prospectus. This prospectus provides you with
a general description of the securities we may offer. Each time
we sell common stock, we will provide a prospectus supplement
that will contain more specific information about the terms of
that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material
information relating to these offerings. We may also add, update
or change in the prospectus supplement (and in any related free
writing prospectus that we may authorize to be provided to you)
any of the information contained in this prospectus or in the
documents that we have incorporated by reference into this
prospectus. We urge you to carefully read this prospectus, any
applicable prospectus supplement and any related free writing
prospectus, together with the information incorporated herein
and therein by reference as described under the heading
Where You Can Find Additional Information, before
buying any of the securities being offered. THIS PROSPECTUS
MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
You should rely only on the information that we have provided or
incorporated by reference in this prospectus, any applicable
prospectus supplement and any related free writing prospectus
that we may authorize to be provided to you. We have not
authorized anyone to provide you with different information. No
dealer, salesperson or other person is authorized to give any
information or to represent anything not contained in this
prospectus, any applicable prospectus supplement or any related
free writing prospectus that we may authorize to be provided to
you. You must not rely on any unauthorized information or
representation. This prospectus is an offer to sell only the
securities offered hereby, and only under circumstances and in
jurisdictions where it is lawful to do so. You should assume
that the information in this prospectus, any applicable
prospectus supplement or any related free writing prospectus is
accurate only as of the date on the front of the document and
that any information we have incorporated by reference is
accurate only as of the date of the document incorporated by
reference, regardless of the time of delivery of this
prospectus, any applicable prospectus supplement or any related
free writing prospectus, or any sale of a security.
This prospectus contains summaries of certain provisions
contained in some of the documents described herein, but
reference is made to the actual documents for complete
information. All of the summaries are qualified in their
entirety by the actual documents. Copies of some of the
documents referred to herein have been filed, will be filed or
will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and
you may obtain copies of those documents as described below
under the heading Where You Can Find Additional
Information.
Our principal address is 3929 Point Eden Way, Hayward,
California 94545. Our telephone number is
(510) 265-9000.
Investing in our securities involves a high degree of risk. You
should carefully review the risks and uncertainties described
under the heading Risk Factors contained in the
applicable prospectus supplement and any related free writing
prospectus, and under similar headings in the other subsequently
filed documents that are incorporated by reference into this
prospectus. Additional risks not presently known to us or that
we currently believe are immaterial may also significantly
impair our business operations.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference
contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, or the
Securities Act, and Section 21E of the Securities Exchange
Act of 1934, or the Exchange Act. These statements involve known
and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements
to be materially different from any future results, performances
or achievements expressed or implied by the forward-looking
statements. These statements may be identified by the words
anticipate, objective, may,
might, should, could,
can, intend, expect,
believe, estimate, predict,
potential, plan or the negative of these
and similar expressions identify forward-looking statements.
Forward-looking statements include, but are not limited to,
statements about:
|
|
|
|
|
our expectations regarding our future expenses, sales and
operations;
|
|
|
|
our estimates of future revenues such as license fees, milestone
payments and royalties from licensing agreements with
collaborators;
|
|
|
|
our reliance on a small number of vendors and contract
manufacturers to supply us with specialized equipment, tools and
components;
|
|
|
|
our limited manufacturing capacity and dependence on contract
manufacturers and collaborators;
|
|
|
|
our ability to establish our own sales, marketing and
distribution capabilities;
|
|
|
|
our ability to receive government grants and other means of
non-dilutive financing;
|
|
|
|
supplementation of our product pipeline with in-licensed
products;
|
|
|
|
expenses associated with payment of license fees, milestone
payments and royalties for in-licensed products;
|
|
|
|
our anticipated cash needs and our estimates regarding our
capital requirements and our need for additional financing;
|
|
|
|
the expected development path and timing of our product
candidates;
|
|
|
|
our expectations regarding the use of Section 505(b)(2) of
the United States Food, Drug and Cosmetic Act and an expedited
development and regulatory process;
|
|
|
|
our ability to obtain and derive benefits from orphan drug
designation;
|
|
|
|
our ability to anticipate the future needs of our customers;
|
|
|
|
our plans for future products and enhancements of existing
products;
|
|
|
|
our growth strategy elements;
|
|
|
|
our intellectual property and our freedom to operate without
infringing on the intellectual property rights of others;
|
|
|
|
the anticipated trends and challenges in the markets in which we
operate; and
|
|
|
|
our ability to attract customers and attain adequate market
acceptance by health professionals and patients.
|
1
These statements reflect our current views with respect to
uncertain future events and are based on imprecise estimates and
assumptions and subject to risk and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. While we believe our plans,
intentions and expectations reflected in those forward-looking
statements are reasonable, these plans, intentions or
expectations may not be achieved. Our actual results,
performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking
statements contained in this prospectus for a variety of
reasons, including those described under the heading Risk
Factors contained in the applicable prospectus supplement
and any related free writing prospectus, and under similar
headings in the other subsequently filed documents that are
incorporated by reference into this prospectus.
All forward-looking statements attributable to us or persons
acting on our behalf are expressly qualified in their entirety
by the risk factors and other cautionary statements set forth in
this prospectus. Other than as required by applicable securities
laws, we are under no obligation, and we do not intend, to
update any forward-looking statement, whether as result of new
information, future events or otherwise.
Except as described in any prospectus supplement or in any
related free writing prospectus that we may authorize to be
provided to you, we currently intend to use the net proceeds
from the sale of the securities offered hereby for research and
development and general corporate and working capital purposes.
We may also use a portion of the proceeds for the potential
acquisition of, or investment in, product candidates,
technologies, formulations or companies that complement our
business, although we have no current understandings,
commitments or agreements to do so.
DESCRIPTION
OF CAPITAL STOCK
Our authorized capital stock consists of 100,000,000 shares
of common stock, no par value per share, and
5,000,000 shares of preferred stock, no par value per
share. The rights and preferences of the preferred stock may be
established from time to time by our board of directors, without
shareholder approval. The following description summarizes some
of the terms of our capital stock. Because it is only a summary,
it does not contain all of the information that may be important
to you. For a complete description you should refer to our
articles of incorporation and bylaws, which are incorporated by
reference as exhibits to the registration statement of which the
prospectus is a part. As of December 13, 2007, there were:
|
|
|
|
|
54,322,705 shares of common stock outstanding held by 212
holders of record; and
|
|
|
|
No shares of preferred stock outstanding.
|
Common
Stock
The holders of our common stock are entitled to one vote for
each share held of record on all matters submitted to a vote of
the shareholders. Our articles of incorporation provide
shareholders the ability to cumulate their votes in the election
of directors; provided, however, that the shareholders shall not
be entitled to cumulate as long as we are a listed
corporation as defined in Section 301.5 of the
California Corporations Code. Subject to preferences that may be
applicable to any then outstanding shares of preferred stock,
holders of our common stock are entitled to receive ratably such
dividends as may be declared by our board of directors out of
funds legally available therefore. In the event of our
liquidation, dissolution or winding up, holders of our common
stock are entitled to share ratably in all assets remaining
after payment of liabilities and the liquidation preference of
any then outstanding shares of preferred stock. Holders of our
common stock have no preemptive rights and no right to convert
their common stock into any other securities. There are no
redemption or sinking fund provisions applicable to our common
stock. All outstanding shares of our common stock are, and all
shares of common stock to be outstanding upon completion of this
offering will be, fully paid and non-assessable.
2
Preferred
Stock
Our board of directors has designated 1,500,000 shares of
preferred stock as Series A Junior Participating Preferred
Stock. The Series A Junior Participating Preferred Stock is
purchasable only upon exercise of the rights under our
shareholder rights plan, discussed below. Our board of directors
has the authority to issue the remaining undesignated shares of
preferred stock in one or more series and to determine the
powers, preferences and rights and the qualifications,
limitations or restrictions granted to or imposed upon any new
series of preferred stock, including dividend rights, dividend
rates, conversion rights, voting rights, terms of redemption,
prices, liquidation preferences, and to fix the number of shares
constituting any series and the designation of such series,
without any further vote or action by our shareholders. The
issuance of preferred stock may have the effect of delaying,
deferring or preventing a change in control transaction and may
adversely affect the voting and other rights of the holders of
our common stock. The issuance of shares of preferred stock with
voting and conversion rights may adversely affect the voting
power of the holders of our common stock, including the loss of
voting control to others. At present, we have no plans to issue
any additional shares of our preferred stock.
Warrants
As of December 13, 2007, we had outstanding warrants to
purchase an aggregate of 426,669 shares of our common stock
with a weighted average exercise price of $10.41 per share. The
warrants expire between March 12, 2008 and
December 22, 2008, with a weighted average remaining term
of 370 days.
Shareholder
Rights Plan
In August 1998, we adopted a shareholder rights plan pursuant to
which we distributed rights to purchase shares of Series A
Junior Participating Preferred Stock as a dividend at the rate
of one right for each share of common stock outstanding. The
rights are designed to guard against partial tender offers and
other abusive and coercive tactics that might be used in an
attempt to gain control of us or to deprive our shareholders of
their interest in our long-term value. The shareholder rights
plan seeks to achieve these goals by encouraging a potential
acquirer to negotiate with our board of directors to redeem the
rights and allow the potential acquirer to acquire our shares
without suffering significant dilution. However, these rights
could deter or prevent transactions that shareholders deem to be
in their interests and could reduce the price that investors or
an acquirer might be willing to pay in the future for shares of
our common stock.
Until the earlier to occur of (i) the date of a public
announcement that a person, entity or group of affiliated or
associated persons have acquired beneficial ownership of 15% or
more of our outstanding common stock, such person or entity
being referred to as an acquiring person, or (ii) 10
business days (or such later date as may be determined by action
of our board of directors prior to such time as any person or
entity acquires beneficial ownership of 15% or more of our
outstanding common stock) following the commencement of, or
announcement of an intention to commence, a tender offer or
exchange offer the consummation of which would result in any
person or entity acquires beneficial ownership of 15% or more of
our outstanding common stock, the earlier of such dates being
called the distribution date, the rights trade with, and are not
separable from, our common stock and are not exercisable.
In the event that any person or group of affiliated or
associated persons becomes a beneficial ownership of 15% or more
of our outstanding common stock, each holder of a right, other
than rights beneficially owned by the acquiring person and its
associates and affiliates (which will thereafter be void), will
for a 60-day
period have the right to receive upon exercise that number of
shares of our common stock having a market value of two times
the exercise price of the right. In the event that we are
acquired in a merger or other business combination transaction
or 50% or more of our consolidated assets or earning power are
sold to an acquiring person, its associates or affiliates or
certain other persons in which such persons have an interest,
each holder of a right will thereafter have the right to
receive, upon the exercise thereof at the then current exercise
price of the right, that number of shares of common stock of the
acquiring company which at the time of such transaction will
have a market value of two times the exercise price of the right.
The rights will expire at the close of business on
September 8, 2008. At any time prior to the earliest of
(i) the day of the first public announcement that a person
has acquired beneficial ownership of 15% or more of our
3
outstanding common stock or (ii) September 8, 2008,
our board of directors may redeem the rights in whole, but not
in part, at a price of $0.001 per right. Following the
expiration of the above periods, the rights become
nonredeemable. Immediately upon any redemption of the rights,
the right to exercise the rights will terminate and the only
right of the holders of rights will be to receive the redemption
price.
The terms of the rights may be amended by our board of directors
without the consent of the holders of the rights, except that,
from and after such time as the rights are distributed, no such
amendment may adversely affect the interest of the holders of
the rights, excluding the interests of an acquiring person.
Anti-Takeover
Effects of Provisions of Our Articles of Incorporation, Our
Bylaws, California Law and Our Other Agreements
Certain provisions of our articles of incorporation, our bylaws
and the California Corporations Code could discourage a third
party from acquiring, or make it more difficult for a third
party to acquire, control of our company without approval of our
board of directors. These provisions could also limit the price
that certain investors might be willing to pay in the future for
shares of our common stock. Certain provisions allow the board
of directors to authorize, without shareholder approval, the
issuance of preferred stock with rights superior to those of the
common stock. We are also subject to the provisions of
Section 1203 of the California Corporations Code which
requires us to provide a fairness opinion to our shareholders in
connection with their consideration of any proposed
interested party reorganization transaction.
We have also adopted an Executive Officer Severance Plan and a
Form of Change of Control Agreement, both of which may provide
for the payment of benefits to our officers in connection with
an acquisition. The severance plan and our change of control
agreements may discourage, delay or prevent a third party from
acquiring us.
Transfer
Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare Trust Company, N.A.
OTC
Bulletin Board Listing
Our common stock is currently quoted on the OTC
Bulletin Board, an electronic quotation service for
securities traded over-the-counter, under the symbol
ARDM.
Shares
Eligible For Future Sale
As of December 13, 2007, Novo Nordisk A/S beneficially
owned 1,573,673 shares of our outstanding common stock.
Pursuant to that certain Amended and Restated Stock Purchase
Agreement we entered into with Novo Nordisk A/S and Novo Nordisk
Pharmaceuticals, Inc. in connection with the January 2005
restructuring of our collaboration with Novo Nordisk, Novo
Nordisk agreed not to transfer or dispose of any shares of our
common stock, with limited exceptions, until January 1,
2009, or the earlier occurrence of certain specified events.
The remaining shares of our common stock are freely tradable,
except that any shares held by our affiliates, as
that term is defined under Rule 144 promulgated under the
Securities Act of 1933, as amended, may only be sold in
compliance with certain requirements of Rule 144, including
volume limitations, manner of sale provisions, notice
requirements and the availability of current public information
about us. In connection with any underwritten public offering
undertaken pursuant to this prospectus, certain of our
directors, officers and shareholders may enter into
lock-up
agreements with the underwriters of such public offering.
We may sell the common stock from time to time pursuant to
underwritten public offerings, negotiated transactions, block
trades or a combination of these methods. We may sell the common
stock to or through underwriters or dealers, through agents, or
directly to one or more purchasers. We may distribute common
stock from time to time in one or more transactions:
|
|
|
|
|
at a fixed price or prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
4
|
|
|
|
|
at prices related to such prevailing market prices; or
|
|
|
|
at negotiated prices.
|
A prospectus supplement or supplements will describe the terms
of the offering of the common stock, including:
|
|
|
|
|
the name or names of the underwriters, if any;
|
|
|
|
the purchase price of the common stock and the proceeds we will
receive from the sale;
|
|
|
|
any over-allotment options under which underwriters may purchase
additional shares of common stock from us;
|
|
|
|
any agency fees or underwriting discounts and other items
constituting agents or underwriters compensation;
|
|
|
|
any public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchange or market on which the common stock may
be listed.
|
Only underwriters named in the prospectus supplement will be
underwriters of the common stock offered by the prospectus
supplement.
If underwriters are used in the sale, they will acquire the
common stock for their own account and may resell the common
stock from time to time in one or more transactions at a fixed
public offering price or at varying prices determined at the
time of sale. The obligations of the underwriters to purchase
the common stock will be subject to the conditions set forth in
the applicable underwriting agreement. We may offer the common
stock to the public through underwriting syndicates represented
by managing underwriters or by underwriters without a syndicate.
Subject to certain conditions, the underwriters will be
obligated to purchase all of the common stock offered by the
prospectus supplement, other than common stock covered by any
over-allotment option. Any public offering price and any
discounts or concessions allowed or reallowed or paid to dealers
may change from time to time. We may use underwriters with which
we have a material relationship. We will describe in the
prospectus supplement, naming the underwriter, the nature of any
such relationship.
We may also sell the common stock directly or through agents
that we designate from time to time. We will name any agent
involved in the offering and sale of the common stock, and we
will describe any commissions we will pay the agent in the
prospectus supplement. Unless the prospectus supplement states
otherwise, our agent will act on a best-efforts basis for the
period of its appointment.
We may authorize agents or underwriters to solicit offers by
certain types of institutional investors to purchase the common
stock from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts
providing for payment and delivery on a specified date in the
future. We will describe the conditions to these contracts and
the commissions we must pay for solicitation of these contracts
in the prospectus supplement.
We may provide agents and underwriters with indemnification
against civil liabilities, including liabilities under the
Securities Act, or contribution with respect to payments that
the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions
with, or perform services for, us in the ordinary course of
business.
Any underwriter may engage in over-allotment, stabilizing
transactions, short-covering transactions and penalty bids in
accordance with Regulation M under the Exchange Act.
Over-allotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit
bids to purchase the underlying shares of common stock so long
as the stabilizing bids do not exceed a specified maximum price.
Syndicate-covering or other short-covering transactions involve
purchases of the common stock, either through exercise of the
over-allotment option or in the open market after the
distribution is completed, to cover short positions. Penalty
bids permit the underwriters to reclaim a selling concession
from a dealer when the shares of common stock originally
5
sold by the dealer are purchased in a stabilizing or covering
transaction to cover short positions. Those activities may cause
the price of the common stock to be higher than it would
otherwise be. If commenced, the underwriters may discontinue any
of the activities at any time.
Any underwriters that are qualified market makers on the OTC
Bulletin Board may engage in passive market making
transactions in the common stock on the OTC Bulletin Board
in accordance with Regulation M under the Exchange Act,
during the business day prior to the pricing of the offering,
before the commencement of offers or sales of the common stock.
Passive market makers must comply with applicable volume and
price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid
at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive
market makers bid, however, the passive market
makers bid must then be lowered when certain purchase
limits are exceeded. Passive market making may stabilize the
market price of the securities at a level above that which might
otherwise prevail in the open market and, if commenced, may be
discontinued at any time.
In compliance with guidelines of the Financial Industry
Regulatory Authority, or FINRA, the maximum consideration or
discount to be received by any FINRA member or independent
broker dealer may not exceed 8% of the aggregate amount of the
securities offered pursuant to this prospectus and any
applicable prospectus supplement.
Cooley Godward Kronish
llp,
San Francisco, California will pass on the validity of the
common stock being offered by this prospectus.
Ernst & Young LLP, independent registered public
accounting firm, has audited our financial statements included
in our Annual Report on
Form 10-K
for the year ended December 31, 2006, as set forth in their
report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial
statements are incorporated by reference in reliance on
Ernst & Young LLPs report, given on their
authority as experts in accounting and auditing.
We have retained Odenberg, Ullakko, Muranishi & Co.
LLP to audit our financial statements for the fiscal year ending
December 31, 2007.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We file annual, quarterly and current reports, proxy and
information statements, and other information with the
Securities and Exchange Commission, or the SEC. You may read and
copy any document we file at the SECs Public Reference
Room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at
1-800-SEC-0330
for more information about the operation of the public reference
room. The SEC maintains an Internet site that contains reports,
proxy and information statements, and other information
regarding issuers, including us, that file electronically with
the SEC. The SECs Internet site can be found at
www.sec.gov.
The SEC allows us to incorporate by reference the information we
file with it, which means that we can disclose important
information to you by referring you to another document that we
have filed separately with the SEC. You should read the
information incorporated by reference because it is an important
part of this prospectus. We incorporate by reference in the
prospectus the following information or documents that we have
filed with the SEC (other than current reports furnished under
Item 2.02 or Item 7.01 of
Form 8-K
and exhibits filed on such form that are related to those items):
|
|
|
|
|
our Annual Report on
Form 10-K
for the year ended December 31, 2006;
|
|
|
|
our Quarterly Reports on
Form 10-Q
for each of the quarters ended March 31, 2007,
June 30, 2007 and September 30, 2007;
|
6
|
|
|
|
|
our Current Reports on
Form 8-K,
filed with the SEC on January 30, 2007, February 26,
2007, April 17, 2007, June 5, 2007, July 11,
2007, July 24, 2007, August 14, 2007,
September 4, 2007 and September 6, 2007;
|
|
|
|
our definitive proxy statement on Schedule 14A for our
annual meeting of shareholders, filed with the SEC on
May 2, 2007; and
|
|
|
|
the description of our common stock contained in our
Registration Statement on
Form 8-A.
|
Any information in any of the foregoing documents will
automatically be deemed to be modified or superseded to the
extent that information in this prospectus or in a later filed
document that is incorporated or deemed to be incorporated
herein by reference modifies or replaces that information.
We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01
of
Form 8-K
and exhibits filed on such form that are related to those items)
made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Exchange Act, until we file a post-effective
amendment that indicates the termination of the offering of the
securities made by this prospectus. Information in those future
filings updates and supplements the information provided in this
prospectus. Any statements in any of those future filings will
automatically be deemed to modify and supersede any information
in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to
the extent that statements in the later filed document modify or
replace those earlier statements.
We will provide to each person, including any beneficial owner,
to whom a prospectus is delivered, without charge upon written
or oral request, a copy of any or all of the documents that are
incorporated by reference into this prospectus but not delivered
with the prospectus, including exhibits which are specifically
incorporated by reference into those documents. Requests should
be directed to: Aradigm Corporation, Attention: General Counsel,
3929 Point Eden Way, Hayward, California 94545.
7
PART II
INFORMATION
NOT REQUIRED IN THE PROSPECTUS
|
|
Item 14.
|
Other
Expenses of Issuance and Distribution.
|
The following table sets forth the estimated costs and expenses,
other than underwriting discounts and commissions, payable by
the registrant in connection with the offering of the securities
being registered. All the amounts shown are estimates, except
for the SEC registration fee and FINRA filing fee.
|
|
|
|
|
SEC registration fee
|
|
$
|
1,842
|
|
FINRA filing fee
|
|
|
6,500
|
|
Accounting fees and expenses
|
|
|
15,000
|
|
Legal fees and expenses
|
|
|
20,000
|
|
Transfer agent fees and expenses
|
|
|
3,000
|
|
Printing and miscellaneous expenses
|
|
|
10,000
|
|
|
|
|
|
|
Total
|
|
$
|
56,342
|
|
|
|
|
|
|
|
|
Item 15.
|
Indemnification
of Directors and Officers.
|
Our articles of incorporation and bylaws include provisions to
(i) eliminate the personal liability of our directors for
monetary damages resulting from breaches of their fiduciary
duty, to the extent permitted by California law, and
(ii) permit us to indemnify our directors and officers,
employees and other agents to the fullest extent permitted by
the California Corporations Code. Pursuant to Section 317
of the California Corporations Code, a corporation generally has
the power to indemnify its present and former directors,
officers, employees and agents against any expenses incurred by
them in connection with any suit to which they are, or are
threatened to be made, a party by reason of their serving in
such positions, so long as they acted in good faith and in a
manner they reasonably believed to be in, or not opposed to, the
best interests of a corporation and, with respect to any
criminal action, they had no reasonable cause to believe their
conduct was unlawful. We believe that these provisions are
necessary to attract and retain qualified persons as directors
and officers. These provisions do not eliminate liability for
breach of the directors duty of loyalty to us or our
shareholders, for acts or omissions not in good faith or
involving intentional misconduct or knowing violations of law,
for any transaction from which the director derived an improper
personal benefit or for any willful or negligent payment of any
unlawful dividend.
We have entered into indemnity agreements with certain officers
and directors that provide, among other things, that we will
indemnify such officer or director, under the circumstances and
to the extent provided for therein, for expenses, damages,
judgments, fines and settlements such officers and directors may
be required to pay in actions, suits or proceedings which they
are or may be made a party by reason of their position as a
director, officer or other agent of us, and otherwise to the
full extent permitted under California law and our bylaws.
We maintain insurance on behalf of any person who is or was a
director or officer against any loss arising from any claim
asserted against him or her and incurred by him or her in that
capacity, subject to certain exclusions and limits to the amount
of coverage.
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
3
|
.1(1)
|
|
Amended and Restated Articles of Incorporation of the Company.
|
|
3
|
.2(2)
|
|
Bylaws of the Company, as amended.
|
|
3
|
.3(3)
|
|
Certificate of Determination of Series A Junior
Participating Preferred Stock.
|
|
3
|
.4(4)
|
|
Certificate of Determination and Preferences of Series A
Convertible Preferred Stock.
|
|
3
|
.5(3)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
3
|
.6(3)
|
|
Certificate of Amendment of Certificate of Determination of
Series A Junior Participating Preferred Stock.
|
II-1
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
3
|
.7(5)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
3
|
.8(5)
|
|
Certificate of Amendment of Certificate of Determination of
Series A Junior Participating Preferred Stock.
|
|
3
|
.9(6)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
4
|
.1
|
|
Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6,
3.7, 3.8 and 3.9.
|
|
4
|
.2(1)
|
|
Specimen common stock certificate.
|
|
5
|
.1
|
|
Opinion of Cooley Godward Kronish LLP.
|
|
23
|
.1
|
|
Consent of Independent Registered Public Accounting Firm.
|
|
23
|
.2
|
|
Consent of Counsel (included in Exhibit 5.1).
|
|
24
|
.1
|
|
Power of Attorney. Reference is made to the signature page.
|
|
|
|
(1) |
|
Incorporated by reference to the Companys
Form S-1
(No. 333-4236),
as amended. |
|
(2) |
|
Incorporated by reference to the Companys
Form 10-Q
filed on August 14, 1998. |
|
(3) |
|
Incorporated by reference to the Companys
Form 10-K
filed for the year ended December 31, 2001. |
|
(4) |
|
Incorporated by reference to the Companys
Form S-3
(No. 333-76584). |
|
(5) |
|
Incorporated by reference to the Companys
Form 10-Q
filed on August 13, 2004. |
|
(6) |
|
Incorporated by reference to the Companys
Form 10-K
filed for the year ended December 31, 2005. |
The undersigned registrant hereby undertakes:
|
|
|
|
(1)
|
To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:
|
|
|
|
|
(i)
|
To include any prospectus required by Section 10(a)(3) of
the Securities Act of 1933;
|
|
|
|
|
(ii)
|
To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the
information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in the
volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of
prospectus filed with the Securities and Exchange Commission
pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the
maximum aggregate offering price set forth in the
Calculation of Registration Fee table in the
effective registration statement; and
|
|
|
|
|
(iii)
|
To include any material information with respect to the plan of
distribution not previously disclosed in the registration
statement or any material change to such information in the
registration statement;
|
provided, however, that paragraphs (1)(i), (1)(ii) and
(1)(iii) above do not apply if the information required to be
included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission
by the registrant pursuant to Section 13 and
Section 15(d) of the Securities Exchange Act of 1934 that
are incorporated by reference in the registration statement, or
is contained in a form of prospectus filed pursuant to
Rule 424(b) that is part of the registration statement.
|
|
|
|
(2)
|
That, for the purpose of determining any liability under the
Securities Act of 1933, each such
post-effective
amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof.
|
II-2
|
|
|
|
(3)
|
To remove from registration by means of a post-effective
amendment any of the securities being registered which remain
unsold at the termination of the offering.
|
|
|
(4)
|
That, for the purpose of determining liability under the
Securities Act of 1933 to any purchaser:
|
|
|
|
|
(A)
|
Each prospectus filed by the registrant pursuant to
Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was
deemed part of and included in the registration
statement; and
|
|
|
|
|
(B)
|
Each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in
reliance on Rule 430B relating to an offering made pursuant
to Rule 415(a)(1)(i), (vii), or (x) for the purpose of
providing the information required by Section 10(a) of the
Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the
date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the
offering described in the prospectus. As provided in
Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to
which that prospectus relates, and the offering of such
securities at that time shall be deemed to be the initial bona
fide offering thereof. Provided, however, that no statement made
in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately
prior to such effective date.
|
|
|
|
|
(5)
|
That, for the purpose of determining liability of the registrant
under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities, the undersigned registrant
undertakes that in a primary offering of securities of the
undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such
securities to such purchaser:
|
|
|
|
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed
pursuant to Rule 424;
|
|
|
|
|
(ii)
|
Any free writing prospectus relating to the offering prepared by
or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;
|
|
|
|
|
(iii)
|
The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the
undersigned registrant; and
|
|
|
|
|
(iv)
|
Any other communication that is an offer in the offering made by
the undersigned registrant to the purchaser.
|
|
|
|
|
(6)
|
That, for purposes of determining any liability under the
Securities Act of 1933, each filing of the registrants
annual report pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plans annual report pursuant
to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
the securities at that time shall be deemed to be the initial
bona fide offering thereof.
|
|
|
(7)
|
That, for purposes of determining any liability under the
Securities Act of 1933, the information omitted from the form of
prospectus filed as part of this registration statement in
reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of this registration statement as
of the time it was declared effective.
|
II-3
|
|
|
|
(8)
|
That, for the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
|
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Exchange
Act and will be governed by the final adjudication of such issue.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on
Form S-3
and has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the
City of Hayward, State of California, on December 20, 2007.
ARADIGM CORPORATION
Igor Gonda
President and Chief Executive Officer
POWER OF
ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Igor Gonda and
Norman Halleen, and each of them, as true and lawful
attorneys-in-fact and agents, with full powers of substitution
and resubstitution, for them and in their name, place and stead,
in any and all capacities, to sign any and all amendments
(including pre-effective and post-effective amendments) to this
registration statement and any additional registration
statements filed pursuant to Rule 462, and to file the
same, with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange
Commission (the SEC), and generally to do all such
things in their names and behalf in their capacities as officers
and directors to enable the registrant to comply with the
provisions of the Securities Act and all requirements of the
SEC, granting unto said attorneys-in-fact and agents, and each
of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in
connection therewith, as fully to all intents and purposes as he
or she might or could do in person, ratifying and confirming all
that said attorneys-in-fact and agents, or any of them, or
their, his or her substitutes or substitute, may lawfully do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed below by
the following persons in the capacities and on the dates
indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Igor
Gonda
Igor
Gonda
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
December 20, 2007
|
|
|
|
|
|
/s/ Norman
Halleen
Norman
Halleen
|
|
Interim Chief Financial Officer (Principal Financial and
Accounting Officer)
|
|
December 20, 2007
|
|
|
|
|
|
/s/ Virgil
D. Thompson
Virgil
D. Thompson
|
|
Chairman of the Board of Directors
|
|
December 20, 2007
|
|
|
|
|
|
/s/ Frank
H. Barker
Frank
H. Barker
|
|
Director
|
|
December 20, 2007
|
|
|
|
|
|
/s/ Stephen
O. Jaeger
Stephen
O. Jaeger
|
|
Director
|
|
December 20, 2007
|
|
|
|
|
|
/s/ John
M. Siebert
John
M. Siebert
|
|
Director
|
|
December 20, 2007
|
II-5
EXHIBIT INDEX
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
3
|
.1(1)
|
|
Amended and Restated Articles of Incorporation of the Company.
|
|
3
|
.2(2)
|
|
Bylaws of the Company, as amended.
|
|
3
|
.3(3)
|
|
Certificate of Determination of Series A Junior
Participating Preferred Stock.
|
|
3
|
.4(4)
|
|
Certificate of Determination and Preferences of Series A
Convertible Preferred Stock.
|
|
3
|
.5(3)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
3
|
.6(3)
|
|
Certificate of Amendment of Certificate of Determination of
Series A Junior Participating Preferred Stock.
|
|
3
|
.7(5)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
3
|
.8(5)
|
|
Certificate of Amendment of Certificate of Determination of
Series A Junior Participating Preferred Stock.
|
|
3
|
.9(6)
|
|
Certificate of Amendment of Amended and Restated Articles of
Incorporation of the Company.
|
|
4
|
.1
|
|
Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6,
3.7, 3.8 and 3.9.
|
|
4
|
.2(1)
|
|
Specimen common stock certificate.
|
|
5
|
.1
|
|
Opinion of Cooley Godward Kronish LLP.
|
|
23
|
.1
|
|
Consent of Independent Registered Public Accounting Firm.
|
|
23
|
.2
|
|
Consent of Counsel (included in Exhibit 5.1).
|
|
24
|
.1
|
|
Power of Attorney. Reference is made to the signature page.
|
|
|
|
(1) |
|
Incorporated by reference to the Companys
Form S-1
(No. 333-4236),
as amended. |
|
(2) |
|
Incorporated by reference to the Companys
Form 10-Q
filed on August 14, 1998. |
|
(3) |
|
Incorporated by reference to the Companys
Form 10-K
filed for the year ended December 31, 2001. |
|
(4) |
|
Incorporated by reference to the Companys
Form S-3
(No. 333-76584). |
|
(5) |
|
Incorporated by reference to the Companys
Form 10-Q
filed on August 13, 2004. |
|
(6) |
|
Incorporated by reference to the Companys
Form 10-K
filed for the year ended December 31, 2005. |